Phase Transition Adjusting Kit for Cell Surface Oligomerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting cell surface molecules, such as death receptor 5 (DR5), have shown limited efficacy or systemic toxicity, and there is a lack of effective methods to enhance the binding activity of ligands to these molecules for improved druggability.
Innovation Solution
A phase transition adjusting kit comprising multiple components, each with a multivalent domain and a specific ligand that binds to a cell surface molecule, is used to drive phase separation and enhance the oligomerization of these molecules, thereby regulating downstream signals and improving targeting specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ligands (antibodies, nanobodies) are used to target cell surface molecules, then binding activity is achieved, but efficacy is extremely limited or no efficacy
Solution Approach 1:
The invention changes the physical state and organizational parameters of the ligand system by inducing phase separation. This transforms conventional monodisperse ligand solutions into systems with phase-separated droplets, fundamentally altering how ligands interact with cell surface molecules and leading to dramatically improved efficacy while maintaining binding activity
Solution Approach 2:
The invention creates a composite system consisting of phase-separated droplets containing multivalent ligands and cell surface molecules. This composite structure, formed through liquid-liquid phase separation, enables enhanced oligomerization and signaling that neither conventional ligands nor phase separation alone could achieve
2Productivity
If tetrameric nanobody TAS266 is used to activate death receptor 5, then activation effect is achieved, but systemic toxicity is high due to inability to specifically target tumors
Solution Approach 1:
The invention applies local quality by concentrating ligands within phase-separated droplets that form at specific locations where cell surface molecules are present. This creates highly localized high-concentration ligand environments that activate receptors only at target sites, avoiding systemic distribution and reducing toxicity while maintaining strong activation effects
Solution Approach 2:
The phase-separated droplets act as intermediaries that mediate between the ligand and cell surface molecules. These droplets concentrate and organize ligands in a controlled manner, enabling specific targeting and controlled activation while preventing uncontrolled systemic effects
3Quantity of substance
If multivalent biological macromolecules undergo phase separation, then liquid phase enriched with macromolecules is formed, but application to enhance ligand binding activity to cell surface molecules has not been reported
Solution Approach 1:
The invention demonstrates the multi-functionality of phase separation by showing it can simultaneously concentrate macromolecules, enhance ligand binding activity, promote oligomerization of cell surface molecules, and improve therapeutic efficacy. This universal mechanism applies across different ligand types and cell surface targets, making it broadly adaptable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit significantly increases the oligomerization of cell surface molecules, enhances signal transduction, and achieves higher targeting specificity compared to ligands without phase separation adjusting activity, potentially leading to more effective therapeutic outcomes.
Implementation Method 1
multivalent biological macromolecules can aggregate through internal multivalent domains, via intermolecular or intramolecular interactions, thereby separating from the common solution phase surrounding the molecules to form an independent liquid phase enriched with the macromolecules. This process is called 'liquid-liquid phase separation' (LLPS, also referred to as 'phase separation' herein) or 'phase transition'.
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3D
AI summary
Provided in the present invention is a novel phase transition adjusting kit, comprising at least two independent components which can interact with each other to specifically drive themselves and cell surface molecules combined thereon to generate phase separation, so as to effectively enhance the cell surface molecular oligomerization and the regulation and control effect on downstream signals, and achieve higher targeting specificity. Further provided are a method for screening the phase transition adjusting kit, a composition or a test kit comprising said kit, and a disease treatment method or a disease prevention method using said kit.